Key result
The platelet-to-lymphocyte ratio was significantly higher in NSTEMI patients who developed angiographic no-reflow after primary percutaneous coronary intervention compared to those with normal reflow (median 108.6 vs. 91.7, p=0.01).
Why the study?
Platelet-to-lymphocyte ratio is a prognostic marker in CAD and predicts long-term mortality after NSTEMI, but its relationship with angiographic no-reflow in NSTEMI was evaluated.
Does the Platelet/Lymphocyte Ratio predict angiographic no-reflow in patients with NSTEMI undergoing primary coronary intervention?
Observational (n=173)
Single-blind
No
Does the Platelet/Lymphocyte Ratio predict angiographic no-reflow in patients with NSTEMI undergoing primary coronary intervention?
Absolute Event Rate: 108.6% vs 91.7%
p-value: p=0.01
PLR may identify NSTEMI patients at higher no-reflow risk; leaves open incremental value and clinical utility.
Inflammation and platelet activation play a central role in the initiation and progression of the atherosclerosis process. The Platelet-to-lymphocyte ratio (PLR) is a new prognostic marker in coronary artery disease. The PLR is a significant independent predictor of long-term mortality after none-ST elevated myocardial infarction (NSTEMI). We aimed to evaluate the relationship between PLR and no-reflow (NR) in patients with NSTEMI.
No takes yet. Share an insight, caveat, or question.
Ramazan et al. (2019) conducted an observational in Non-ST Segment Elevation Acute Myocardial Infarction (NSTEMI) (n=173). Platelet-to-lymphocyte ratio (PLR) vs. Normal reflow group was evaluated on Platelet-to-lymphocyte ratio (PLR) in patients with angiographic no-reflow versus normal reflow (p=0.01). The platelet-to-lymphocyte ratio was significantly higher in NSTEMI patients who developed angiographic no-reflow after primary percutaneous coronary intervention compared to those with normal reflow (median 108.6 vs. 91.7, p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: